> Chemicals & Drugs > Pharmacologic Substance > Zidovudine

Zonal →

Zidovudine

Zidovudine, also known as AZT, is a nucleoside reverse transcriptase inhibitor used in the treatment of HIV/AIDS.
It is effective in delaying the progression of the disease and reducing the risk of opportunistic infections.
Zidovudine works by interfering with the reverse transcriptase enzyme, which is essential for the replication of the HIV virus.
This medication is often used in combination with other antiretroviral drugs as part of a comprehensive treatment regimen.
Researchers and clinicians can optimize their Zidovudine studies using PubComapre.ai, an AI-driven platform that helps identify the best protocols from literature, preprints, and patents, enhancing reproducibility and accuracy.

Most cited protocols related to «Zidovudine»

Early ART in HIV-Infected Infants

Cited 50 times

The Children with HIV Early Antiretroviral Therapy (CHER) trial is a phase 3, randomized, open-label trial conducted by the Comprehensive International Program for Research in AIDS — South Africa in collaboration with the Medical Research Council Clinical Trials Unit, United Kingdom, and the Division of AIDS (DAIDS) of the National Institutes of Health (NIH). The study is being conducted in two centers in South Africa: the Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, in Soweto, and the Children's Infectious Diseases Clinical Research Unit, Tygerberg Children's Hospital, in Cape Town.
We enrolled infants 6 to 12 weeks of age who had HIV infection (defined by a positive polymerase-chain-reaction [PCR] test for HIV-1 DNA and a plasma HIV-1 RNA level on PCR of >1000 copies per milliliter) and a CD4 percentage of 25% or more. Exclusion criteria are listed in the Supplementary Appendix, available with the full text of this article at www.nejm.org. Infants were randomly assigned to receive one of three treatments: early limited antiretroviral therapy for 96 weeks, early limited antiretroviral therapy for 40 weeks, or deferred therapy. Immunologic criteria for initiating antiretroviral therapy in the deferred-therapy group or reinitiating antiretroviral therapy in the early-therapy groups were a CD4 percentage of less than 20%5 or, in the case of children younger than 12 months, a CD4 percentage of less than 25% or a CD4 count of less than 1000 cells per cubic millimeter, according to World Health Organization (WHO) guidelines updated in 2006.6 Clinical criteria for initiating or reinitiating antiretroviral therapy7 were Centers for Disease Control and Prevention (CDC) stage C or investigator-selected (severe) stage B events (see the Supplementary Appendix), including symptomatic lymphoid interstitial pneumonitis, bronchiectasis, nephropathy, cardiomyopathy, and failure to thrive. GlaxoSmithKline provided lamivudine and zidovudine, and the South African Department of Health provided lopinavir–ritonavir. Written informed consent was obtained from the parents or legal guardians of all the infants. The authors vouch for the completeness and accuracy of the data.

Violari A., Cotton M.F., Gibb D.M., Babiker A.G., Steyn J., Madhi S.A., Jean-Philippe P, & McIntyre J.A. (2008). Early Antiretroviral Therapy and Mortality among HIV-Infected Infants. The New England journal of medicine, 359(21), 2233-2244.

Publication 2008

Acquired Immunodeficiency Syndrome Bronchiectasis Cardiomyopathies CD4+ Cell Counts Cells Child Communicable Diseases Cuboid Bone Early Therapy Failure to Thrive Group Therapy HIV-1 HIV Infections Infant Kidney Diseases Lamivudine Legal Guardians lopinavir-ritonavir drug combination Lymphoid Interstitial Pneumonia Parent Plasma Polymerase Chain Reaction Southern African People Therapeutics Youth Zidovudine

Pneumococcal Vaccine Response in HIV-Exposed Infants

Cited 28 times

The study enrolled a priori four groups of children aged 6 to 12 weeks. These included 2 groups of HIV infected infants, co-enrolled from the Children with HIV Early Antiretroviral (CHER) Study in South Africa, 5 (link) with CD4+ T-lymphocyte cells ≥25% randomized to initiate ART immediately (HIV+/ART+ group); or ART was initiated when clinically or immunologically indicated (HIV+/ART− Group). 6 The ART regimen included zidovudine, lamivudine and lopinavir/ritonavir. Additionally, two cohorts of HIV non-infected infants were prospectively enrolled in parallel to the HIV infected children including: i. infants born to HIV infected mothers who were HIV PCR (Roche Amplicor Version 1.5 RNA PCR) negative at baseline and one month after the third dose of Vaccine (M+/I−) and ii. infants born to mothers seronegative for HIV after 24 weeks of gestational age during pregnancy and who were HIV ELISA seronegative at study-enrolment (i.e. M−/I−).
Additional participant-eligibility criteria included absence of intercurrent illness within 72 hours of enrolment, no Grade 3 or 4 clinical or laboratory toxicity as per DAIDS Pediatric Adverse Experiences,7 birth weight of at least 2000 grams, participation in the CHER study for HIV infected infants, absence of receipt of any blood products prior to study entry, any immunomodulating medication for more than two weeks within one week of possible enrolment
Infants were enrolled between April 2005 and June 2006 and scheduled to receive three doses of 7-valent pneumococcal conjugate vaccine (i.e. Prevnar®; Wyeth Vaccines, NJ, USA) at 6 to 12, 9 to 18 and 12 to 24 weeks of age. Infants received other scheduled childhood vaccines, included in the public immunization program, concurrently with Prenar®.
Immune response to the primary series of Vaccine was measured 3 to 6 weeks after the third dose using serum from venous blood which had been centrifuged, aliquotted and stored at –20 to −70°C until processing at the Respiratory and Meningeal Pathogens Research Unit (RMPRU), Johannesburg, South Africa. A standardized enzyme immunoassay (EIA), including adsorption with 22F polysaccharide, was used to test for vaccine-serotype specific capsular IgG antibody concentrations as described. 8 (link) 9 (link)
The functionality of the antibodies post vaccination was determined by opsonophagocytic killing assay (OPA) for serotypes 9V, 19F and 23F using differentiated HL-60 cells as described.8 (link) 10 (link) Lower antibody concentrations required for 50% killing activity on OPA is suggestive of superior antibody functional activity. Detectable killing activity on OPA was defined as a titer of ≥8.
For quality assurance, a quality control serum from a vaccinated volunteer was included on each plate. The coefficient of variation for the control sera were <40% for all serotypes.

Madhi S.A., Adrian P., Cotton M.F., McIntyre J.A., Jean-Philippe P., Meadows S., Nachman S., Käyhty H., Klugman K.P, & Violari A. (2010). Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. The Journal of infectious diseases, 202(3), 355-361.

Publication 2010

Adsorption Antibodies Biological Assay Birth Weight Blood Capsule CD4 Positive T Lymphocytes Cells Child Childbirth Eligibility Determination Enzyme-Linked Immunosorbent Assay Enzyme Immunoassay Gestational Age HIV-2 HL-60 Cells Immunization Programs Immunoglobulin G Infant Lamivudine lopinavir-ritonavir drug combination Meninges Mothers pathogenesis Pharmaceutical Preparations Pneumococcal Vaccine Polysaccharides Pregnancy Prevnar Respiratory Rate Response, Immune Serum Treatment Protocols Vaccination Vaccines Veins Voluntary Workers Zidovudine

Preventing HIV Transmission in Botswana

Cited 23 times

Between July 2006 and May 2008, we enrolled pregnant women with HIV-1 infection in the Mma Bana Study (meaning “mother of the baby” in Setswana) in southern Botswana. Women with CD4+ cell counts of 200 or more were randomly assigned (in permuted blocks stratified according to clinical site) to receive either 300 mg of abacavir, 300 mg of zidovudine, and 150 mg of lamivudine coformulated as Trizivir (GlaxoSmith-Kline) twice daily (the NRTI group) or 400 mg of lopinavir and 100 mg of ritonavir coformulated as Kaletra (Abbott) with 300 mg of zidovudine and 150 mg of lamivudine coformulated as Combivir (GlaxoSmithKline) twice daily (the protease-inhibitor group). Women with CD4+ cell counts of less than 200 cells per cubic millimeter or with an acquired immunodeficiency syndrome (AIDS)–defining illness received standard-of-care treatment for Botswana: 200 mg of nevirapine, 300 mg of zidovudine, and 150 mg of lamivudine twice daily (after a 2-week lead-in period of oncedaily nevirapine at a dose of 200 mg) (the observational group). Women in the randomized groups began to receive HAART between 26 and 34 weeks’ gestation and continued it through weaning or 6 months post partum (whichever occurred first), and women in the observational group began to receive HAART between 18 and 34 weeks’ gestation and continued treatment indefinitely. We report results for the primary end points at 6 months post partum.
Infants received single-dose nevirapine (6 mg) at birth and received zidovudine (4 mg per kilogram of body weight twice daily) from birth through 4 weeks. Women were counseled to exclusively breast-feed and to complete weaning 3 days before the 6-month study visit. Infants were provided free formula and foods from the time of weaning (whenever it occurred) through 12 months.
Study drugs were provided by GlaxoSmith-Kline (Trizivir and Combivir) and Abbott Pharmaceuticals (Kaletra), but these companies had no other role in the design of the study, the accrual or analysis of the data, the preparation of the manuscript, or the decision to submit the manuscript for publication. The Botswana government provided nevirapine, Combivir, additional medications, and some laboratory testing. The Health Research Development Committee of Botswana and the Human Subjects Committee of the Harvard School of Public Health approved the study protocol and amendments. An independent data and safety monitoring board reviewed safety and efficacy data approximately every 6 months. The full study protocol including the statistical-analysis plan, is available with the full text of this article at NEJM.org. All authors vouch for the completeness and veracity of the reported data and analyses and attest that the study as reported conforms with the protocol.

Shapiro R.L., Hughes M.D., Ogwu A., Kitch D., Lockman S., Moffat C., Makhema J., Moyo S., Thior I., McIntosh K., van Widenfelt E., Leidner J., Powis K., Asmelash A., Tumbare E., Zwerski S., Sharma U., Handelsman E., Mburu K., Jayeoba O., Moko E., Souda S., Lubega E., Akhtar M., Wester C., Tuomola R., Snowden W., Martinez-Tristani M., Mazhani L, & Essex M. (2010). Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana. The New England journal of medicine, 362(24), 2282-2294.

Publication 2010

abacavir Acquired Immunodeficiency Syndrome Antiretroviral Therapy, Highly Active Body Weight CD4+ Cell Counts Cells Childbirth Clinical Trials Data Monitoring Committees Combivir Cuboid Bone Food HIV-1 Homo sapiens Infant Infection Kaletra Lamivudine Lopinavir Mothers Nevirapine Pharmaceutical Preparations Pregnancy Pregnant Women Protease Inhibitors Ritonavir Trizivir Woman Zidovudine

Evaluating Antiretroviral and Nutritional Interventions for HIV-Exposed Infants

Cited 20 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2008

Dietary Supplements Dysentery Food Infant Maize Malaria Meningitis Mothers Nevirapine Obstetric Delivery Obstetric Labor Pharmaceutical Preparations Pneumonia Septicemia Treatment Protocols Tuberculosis Vitamin A Woman Zidovudine

Antiretroviral Therapy in HIV-Infected Children

Cited 15 times

In cohort 1 of the P1060 trial, we enrolled HIV-infected children between 6 and 36 months of age who had had documented exposure to a single dose of nevirapine for perinatal prevention of HIV transmission. According to version 1.0 of the protocol, the child could be eligible for inclusion if either the mother or the child had received nevirapine, but the protocol was subsequently amended to require specifically that the child had received nevirapine. The protocol, including the statistical analysis plan, is available with the full text of this article at NEJM.org. The authors attest that the study was performed in accordance with the protocol and the statistical analysis plan.
To ensure that the children were infected with HIV during the time of exposure to single-dose nevirapine — and not later during breast-feeding — the inclusion criteria specified that the children had to have received the diagnosis of HIV infection or to have had an acquired immunodeficiency syndrome (AIDS)–defining event by 60 days of age or that they had to have been formula-fed exclusively from birth. In addition, children had to be eligible for treatment according to World Health Organization (WHO) criteria and to have baseline plasma HIV type 1 (HIV-1) RNA levels of more than 5000 copies per milliliter. Children who were undergoing treatment for tuberculosis were ineligible. Enrollment was stratified according to age (<12 months vs. ≥12 months), and children were randomly assigned, in a 1:1 ratio, to an NNRTI-based regimen of nevirapine, zidovudine, and lamivudine or a protease-inhibitor–based regimen of ritonavir-boosted lopinavir, zidovudine, and lamivudine. In the event of a toxic reaction or contraindication to zidovudine, stavudine was substituted.
Children were enrolled at nine sites in Africa: four in South Africa and one each in Zimbabwe, Zambia, Malawi, Uganda, and Tanzania. The study was approved by the ethics review committee at each local site, the institutional review board at each partner U.S. institution, and the Ministry of Health, where needed. Written informed consent was obtained from the children’s parents or legal guardians. Study visits were conducted 2 and 4 weeks after the initiation of treatment, every 4 weeks until week 16, at week 24, and every 12 weeks thereafter. Plasma HIV-1 RNA levels were measured at site laboratories with the use of the standard Roche Amplicor v1.5 test kit (eight sites) or the Abbott RealTime HIV-1 assay (one site), with all the laboratories participating in the Division of Acquired Immunodeficiency Syndrome (DAIDS) Quality Assurance Program. Tests for HIV resistance were performed retrospectively on plasma samples at a single laboratory with the use of the ViroSeq HIV-1 Genotyping System, versions 2.7 and 2.8 (Celera), and ViroSeq software (in which lower-end sensitivity requires that approximately 20% of the virus population possess a resistance mutation for detection).

Palumbo P., Lindsey J.C., Hughes M.D., Cotton M.F., Bobat R., Meyers T., Bwakura-Dangarembizi M., Chi B.H., Musoke P., Kamthunzi P., Schimana W., Purdue L., Eshleman S.H., Abrams E.J., Millar L., Petzold E., Mofenson L.M., Jean-Philippe P, & Violari A. (2010). Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure. The New England journal of medicine, 363(16), 1510-1520.

Publication 2010

Acquired Immunodeficiency Syndrome Biological Assay Birth Child Ethics Committees, Research HIV-1 HIV Infection Diagnosis Hypersensitivity Lamivudine Legal Guardians lopinavir-ritonavir drug combination Mothers Mutation Nevirapine Parent Plasma Protease Inhibitors Stavudine Testing, AIDS Transmission, Communicable Disease Treatment Protocols Tuberculosis Virus Zidovudine

Most recents protocols related to «Zidovudine»

Generation of In-frame Deletion Mutants

In-frame deletion mutants were generated using the suicide plasmid pEXG2 as described in Klein et al.^{34 (link)} or its derivate pEXTK. In pEXTK, the sacB gene is replaced by a thymidine kinase gene. If pEXTK based mutator plasmids were used in the mutagenesis procedure, the positive selection to obtain a second crossover was performed by incubating merodiploidic clones for 3 h in 5 ml LB medium containing IPTG (1 mM). Subsequently, bacteria were positively selected by streaking bacteria on LB agar plates containing 200 µg/ml azidothymidine (Acros Organics) and 1 mM IPTG. Bacteria were then tested for loss of gentamicin sensitivity and mutants were verified by PCR as described previously^{34 (link)}. In brief, genomic DNA was isolated using the DNeasy Ultraclean Microbial Kit (Qiagen) and approximately 20 ng DNA was used to perform PCR using Mango Mix (Bioline), primers (Sigma-Aldrich) and water. Two primer pairs were used, namely (i) gene of interest (GOI) seqF and GOI seqR and (ii) GOI seqF and GOI insideR to distinguish between wildtype and mutant. The generated mutants and the primers used in this study are listed in Supplementary Data 1 or 2, respectively.

Eggers O., Renschler F.A., Michalek L.A., Wackler N., Walter E., Smollich F., Klein K., Sonnabend M.S., Egle V., Angelov A., Engesser C., Borisova M., Mayer C., Schütz M, & Bohn E. (2023). YgfB increases β-lactam resistance in Pseudomonas aeruginosa by counteracting AlpA-mediated ampDh3 expression. Communications Biology, 6, 254.

Full text: Click here

Publication 2023

Agar Bacteria Clone Cells Deletion Mutation Genes Genome Gentamicin Hypersensitivity Isopropyl Thiogalactoside Mangifera indica Mutagenesis Oligonucleotide Primers Plasmids Reading Frames Thymidine Kinase Zidovudine

Cohort Study of HIV+ Pregnant Women

This retrospective cohort study comprised singleton WLH pregnancies followed up at our obstetrics department (Hospital das Clínicas, São Paulo University Medical School, São Paulo – Brazil) between 2006 and 2019.
A database search was conducted to identify all cases of WLH evaluated in our department during the study period. Cases of multiple pregnancies, loss to follow-up, delivery at other hospitals, absence of prenatal care, unawareness of HIV diagnosis before delivery, and unavailability of hospital charts were not included.
Patient charts were revised, and data regarding maternal demographic characteristics, HIV infection, ART exposure, and obstetric and neonatal outcomes were assessed. HIV-related aspects considered were the type of transmission (perinatally vs. behaviorally), time of diagnosis, Viral Load (VL), CD4+ cell count, signs of immunodeficiency (CD4+ cell count < 200 mm³ or opportunistic infections), and genotype testing. Laboratory analyses were considered at baseline (first appointment) and 34 weeks of gestation.
Patients were considered to have PHIV if there was clear information on patients’ charts about such a type of transmission, based on HIV-positive mothers and diagnosis during childhood. Other cases were classified as Behaviorally acquired HIV (BHIV) cases.
The perinatal outcomes assessed included gestational age at delivery, preterm birth, low birth weight (< 2500 g), gestational diabetes, preeclampsia, fetal growth restriction, preterm labor, abnormal fetal well-being, and HIV Mother-To-Child Transmission (MTCT).
Throughout the study period, there were different guidelines for caring for pregnant WLH. Follow-up of this group of patients comprised regular prenatal appointments, first and second-trimester morphology scans, and regular assessment of fetal growth and wellbeing. All patients were prescribed ART, which consisted of three active antiretroviral drugs. The patients were assisted by a multidisciplinary team consisting of obstetricians, infectologists, psychologists, and social workers.
Historically, local practices regarding pregnant WLH tended toward elective cesarean delivery, irrespective of VL. Such policies have changed, and vaginal births have recently been encouraged. During the study period, zidovudine intrapartum prophylaxis and neonatal zidovudine syrup were routinely recommended to all the patients. Breastfeeding was contraindicated.
Indications for genotype testing during the study period included virological failure and, most recently, ART-naïve pregnant women. Data on genotype testing were assessed retrospectively, based on available test results on patients’ charts and the “Brazilian National Network of CD4+/CD8+ Lymphocyte Count and Viral Load” (SISCEL).

Osmundo GD J.u.n.i.o.r., da Costa R.A., Ruocco R.M, & Francisco R.P. (2023). Pregnancy in women living with perinatally acquired HIV: Perinatal outcomes and drug resistance profile. Clinics, 78, 100174.

Full text: Click here

Publication 2023

Care, Prenatal CD4+ Cell Counts Cesarean Section Diagnosis Fetal Growth Fetal Growth Retardation Genotype Gestational Age Gestational Diabetes HIV Infections Immunologic Deficiency Syndromes Infant, Newborn Maternal-Fetal Infection Transmission Mothers Obstetric Delivery Obstetrician Opportunistic Infections Patients Pharmaceutical Preparations Pre-Eclampsia Pregnancy Pregnant Women Premature Birth Premature Obstetric Labor Radionuclide Imaging Transmission, Communicable Disease Vagina Zidovudine

Antiviral Activity Evaluation Assay

The IC₅₀ values for the examined extracts were determined as previously described [5 (link), 6 (link)]. Briefly, Vero-E6 cells were dispensed evenly into the 96-well tissue cultivation plates and were cultured overnight at 37°C with 5% CO₂ to reach 80–90% confluency. The cell monolayers were then exposed to pre-incubated sample/virus mixtures containing 100 TCID50 (Median Tissue Culture Infectious Dose) of the virus. The treated cell monolayers are kept the mixtures containing different sample concentrations (50) for 1 h at ambient temperature and then washed out with 1x phosphate buffer saline (PBS). Subsequently, 100 μl of infection media DMEM supplemented with 1% pen/strep and 0.2% Bovine Serum Albumin (BSA) were added. The cells were then kept for 72 h at 37°C in an incubator with 5% CO₂. Eventually, cell monolayers were fixed with 100 μl of 4% para-formaldehyde for 20 minutes, stained further with 0.1% crystal violet in distilled water at RT for 15 min and destained with absolute methanol. The absorption intensity of the solubilized crystal violet color was then measured at 570 nm using an AnthosZenyth 200rt plate reader. In comparison to the virus and cell controls, the compound’s 50% inhibitory concentration (IC₅₀) was calculated using GraphPad prism software by plotting the log concentration against normalized responses.

Hemdan B.A., Mostafa A., Elbatanony M.M., El-Feky A.M., Paunova-Krasteva T., Stoitsova S., El-Liethy M.A., El-Taweel G.E, & Abu Mraheil M. (2023). Bioactive Azadirachta indica and Melia azedarach leaves extracts with anti-SARS-CoV-2 and antibacterial activities. PLOS ONE, 18(3), e0282729.

Full text: Click here

Publication 2023

Buffers Cells Formaldehyde Infection Methanol Phosphates prisma Psychological Inhibition Saline Solution Serum Albumin, Bovine Streptococcal Infections Tissues Vero Cells Violet, Gentian Virus Zidovudine

Cytotoxicity Screening of Diverse Compounds

Two thousand cells per well were seeded in a 96-well plate. After the cells adhered to the plate, the different concentrations of drugs (zidovudine, andrographolide, amoxicillin, cefixime, sulfasalazine, nifuratel, NFZ, nifursol, napabucasin, olaparib, and disulfiram purchased from MCE;nifurtimox provided by TargetMol) diluted in culture medium were added, with DMSO (Biotopped Amresco) as control. The cells were cultured at 37°C and 5% CO₂ for 72 hours. Then, 10 μL of CCK8 (MCE, USA) solution and 90 μL of corresponding medium were added into each well, and cells were incubated for an additional 2 hours, followed by measuring the absorbance at 450 nm using a FilterMax F5 filter microplate reader.

Li C., Zhang J., Wu Q., Kumar A., Pan G, & Kelvin D.J. (2023). Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer. Molecular Cancer Therapeutics, 22(3), 306-316.

Publication 2023

Amoxicillin andrographolide Cefixime Cells Disulfiram napabucasin Nifuratel nifursol Nifurtimox olaparib Pharmaceutical Preparations Sulfasalazine Sulfoxide, Dimethyl Zidovudine

Quantifying Cell Death by NAMPT Inhibitors

To determine the cell death induced by NAMPT inhibitors, malignant cells were stained with ANNEXIN-V (ANXN, eBioscience, BMS306FI/300) and 7-aminoactinomycin D (7AAD, Immunotech, A07704) as described by the manufacturer and analyzed using flow cytometry. Dead cells were identified as ANXN+7AAD+ /7AAD+ and early apoptotic cells as ANXN+ 7AAD-. Specific cell death induced by inhibitors was calculated using the following formula: percent of cell death induced by compound = [(S – C) / (100 – C)] × 100; where S = treated sample cell death and C = untreated sample cell death.

Biniecka P., Matsumoto S., Belotti A., Joussot J., Bai J.F., Majjigapu S.R., Thoueille P., Spaggiari D., Desfontaine V., Piacente F., Bruzzone S., Cea M., Decosterd L.A., Vogel P., Nencioni A., Duchosal M.A, & Nahimana A. (2023). Anticancer Activities of Novel Nicotinamide Phosphoribosyltransferase Inhibitors in Hematological Malignancies. Molecules, 28(4), 1897.

Full text: Click here

Publication 2023

7-aminoactinomycin D Annexin A5 Apoptosis Cell Death Cells Flow Cytometry inhibitors nicotinamide phosphoribosyltransferase, human Zidovudine

Top products related to «Zidovudine»

Zidovudine by Merck Group

Sourced in United States, Germany

Zidovudine is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV infection. It is a laboratory product designed for research and clinical use.

Dimethyl sulfoxide (dmso) by Merck Group

Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh

DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.

Zidovudine by Selleck Chemicals

Sourced in Germany, China

Zidovudine is a laboratory reagent used for research purposes. It is a nucleoside reverse transcriptase inhibitor that can be used to study HIV and other retroviruses.

Nevirapine by Merck Group

Sourced in United States, United Kingdom

Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection. It is a laboratory product manufactured by Merck Group for research purposes.

Alamethicin by Merck Group

Sourced in United States, Sao Tome and Principe, Germany, Belgium

Alamethicin is a peptide-based laboratory product manufactured by Merck Group. It functions as an ion channel-forming polypeptide, facilitating the movement of small molecules across lipid bilayers in controlled experimental settings.

Azidothymidine azt by Merck Group

Sourced in United States

Azidothymidine (AZT) is a laboratory reagent and anti-viral medication. It is a synthetic nucleoside analog that inhibits the replication of retroviruses, such as HIV. AZT functions by interfering with the reverse transcriptase enzyme, which is essential for the replication of retroviruses.

Acetonitrile by Merck Group

Sourced in Germany, United States, Italy, India, China, United Kingdom, France, Poland, Spain, Switzerland, Australia, Canada, Brazil, Sao Tome and Principe, Ireland, Belgium, Macao, Japan, Singapore, Mexico, Austria, Czechia, Bulgaria, Hungary, Egypt, Denmark, Chile, Malaysia, Israel, Croatia, Portugal, New Zealand, Romania, Norway, Sweden, Indonesia

Acetonitrile is a colorless, volatile, flammable liquid. It is a commonly used solvent in various analytical and chemical applications, including liquid chromatography, gas chromatography, and other laboratory procedures. Acetonitrile is known for its high polarity and ability to dissolve a wide range of organic compounds.

Prostratin by Merck Group

Sourced in United States

Prostratin is a chemical compound that has been studied for its potential pharmaceutical applications. It is a protein kinase C (PKC) activator, which means it can stimulate the activity of PKC enzymes. PKC enzymes play various roles in cellular processes, and modulating their activity can have effects on different biological systems. The core function of Prostratin is to act as a PKC activator, but its specific intended uses and applications require further research and development.

Didanosine by Merck Group

Didanosine is a laboratory chemical used for research purposes. It functions as a nucleoside reverse transcriptase inhibitor (NRTI), which is a class of antiretroviral drugs. Didanosine is commonly used in the study of viral infections and related treatments.

Tenofovir by Selleck Chemicals

Sourced in Germany

Tenofovir is a chemical compound used in the manufacturing of various laboratory equipment. It serves as a key component in the production of specific lab instruments and devices. The core function of Tenofovir is to enable the creation of these specialized laboratory tools, without interpretation or extrapolation on its intended use.

More about "Zidovudine"

Zidovudine, also known as AZT, is a nucleoside reverse transcriptase inhibitor (NRTI) used in the treatment of HIV/AIDS.
It is effective in delaying the progression of the disease and reducing the risk of opportunistic infections.
Zidovudine works by interfering with the reverse transcriptase enzyme, which is essential for the replication of the HIV virus.
This medication is often used in combination with other antiretroviral drugs, such as Nevirapine, Didanosine, and Tenofovir, as part of a comprehensive treatment regimen.
Researchers and clinicians can optimize their Zidovudine studies using PubCompare.ai, an AI-driven platform that helps identify the best protocols from literature, preprints, and patents, enhancing reproducibility and accuracy.
PubCompare.ai can also be utilized for researching related compounds like DMSO, Alamethicin, Acetonitrile, and Prostratin, which may have synergistic effects or provide insights into Zidovudine's mechanism of action.
By leveraging the power of PubCompare.ai, researchers can streamline their Zidovudine studies, accessing the most relevant and reliable information from a vast pool of scientific literature and data.
This AI-powered tool can help enhance the efficiency, accuracy, and reproducibility of Zidovudine research, ultimately accelerating the development of more effective treatments for HIV/AIDS.